Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 406Uterine Cervical Neoplasms 400Endometrial Neoplasms 197Carcinoma, Ovarian Epithelial 100Breast Neoplasms 72Fallopian Tube Neoplasms 71Uterine Cervical Dysplasia 68Neoplasms 51Colorectal Neoplasms 42Pancreatic Neoplasms 40Stomach Neoplasms 39Peritoneal Neoplasms 32Papillomavirus Infections 32Recurrence 31Uterine Neoplasms 29Vulvar Neoplasms 27Prostatic Neoplasms 26Lung Neoplasms 24Esophageal Neoplasms 23Urinary Bladder Neoplasms 22Melanoma 20Colonic Neoplasms 20Head and Neck Neoplasms 19Gynecologic Cancer 19Endometrial Hyperplasia 18Neoplasm Metastasis 17Carcinoma, Non-Small-Cell Lung 17Squamous Intraepithelial Lesions 16Sarcoma 16Ovarian Cysts 15

Interventions

liposomal doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Ovarian Neoplasm Epithelial × Gynecologic × Clear all
NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Seoul National University Hospital

Phase 2 Unknown
44 enrolled
Gynecologic

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡